Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · SHIVALIK RASAYAN LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
SHIVALIK RASAYAN LIMITED is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY22
FY23
FY24
FY25
FY26
Revenue
215
234
273
312
368
EBITDA (ex other income)
47
43
39
40
46
margin %
21.8
18.3
14.4
12.9
12.4
Owners' profit
0
30
16
17
12
EPS, as reported (₹)
18.12
15.02
10.75
10.60
7.71
ROE % · ROCE %
9.4 · 10.5
7.1 · 8.3
3.6 · 5.8
3.8 · 5.9
3.0 · 4.9
Debt / equity (x)
0.11
0.14
0.15
0.18
0.19
Cash from operations
10
(19)
(6)
(8)
(34)
Capex
(25)
(63)
(79)
(21)
(23)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SHIVALIK RASAYAN LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Q1 FY27
Revenue
82
85
69
89
94
82
103
96
Profit before tax
5
8
6
4
5
4
8
6
Net profit
4
7
5
3
4
4
7
5
EPS (₹)
2.58
3.30
2.62
1.02
1.93
1.71
2.87
2.16
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
Segment
Revenue, ₹ crore
Share %
Agrochemicals
151
41.1
Active Pharma Ingredient (API)
8
2.2
Pharma Formulation
198
53.7
Unallacated other operating revenue
3
0.8
Active Pharma ingredient (API)
1
0.3
Unallocated other operating revenue
7
1.9
Total, before eliminations
368
100.0
Source: the filed segment block, four quarters summed.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SHIVALIK RASAYAN LIMITED · 29 October 2026Page 3 of 3
Exhibit 4: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
29 Sept 2026 · All 7 resolutions passed at Shivalik Rasayan 48th AGM; dividend declared
board shareholder meetings
medium
—
—
29 Sept 2026 · Denmark investor Ginnerup Capital picks 5.34 percent stake via convertible warrants
3 Sept 2026 · 48th AGM on Sep 28, 2026 with Final Dividend of Re 0.50 per share
board shareholder meetings
low
—
—
25 Aug 2026 · Shivalik Rasayan EGM approves preferential share and warrant issuance
board shareholder meetings
medium
—
—
24 Aug 2026 · Former Director sells 25000 shares worth Rs 68.31 lakh on NSE and BSE
compliance
minimal
—
—
22 Aug 2026 · EGM results: preferential share and warrant issue approved by shareholders
board shareholder meetings
medium
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
